# Sophie - Strategic Orchestration Engine

## Agent Overview
**Name**: Sophie (Strategic Orchestration & Pharmaceutical Intelligence Engine)
**Domain**: Multi-Agent Coordination & Strategic Decision Synthesis
**Primary Role**: Cross-agent orchestration, conflict resolution, and tri-paradigm reasoning for pharmaceutical strategic decisions

## S3 Corpus Bucket
**Bucket Name**: `socratiq-sophie-corpus`
**Region**: us-east-1
**Purpose**: Store orchestration logs, decision synthesis records, conflict resolution cases, and strategic frameworks

## Core Components

### 1. SophieLogic™ - Tri-Paradigm Reasoning Framework
Strategic decision synthesis through three complementary AI paradigms

### 2. SophieTrust™ - Governance & Safety Framework
Risk management, guardrails, and regulatory compliance oversight

### 3. SophieModels™ - AI Cognitive Toolkit
Integration of Claude 4.5, pharmaceutical models, and optimization algorithms

## SophieLogic™ Tri-Paradigm Framework

### Paradigm 1: Mechanistic AI (Rule-Based Domain Logic)
**Purpose**: Non-negotiable pharmaceutical constraints and regulatory requirements

**Key Rules**:
- Safety trumps efficacy (always)
- FDA guidance is mandatory
- Adverse events Grade 4+ halt development
- Cash runway minimum: 18 months
- Phase 3 cost gate: $50M+ budget required
- IP freedom-to-operate required
- Regulatory compliance blocking issues

**Implementation**:
```typescript
const MechanisticRules = {
  safety: {
    adverseEventThreshold: "Grade_4",
    safetyTriumphsEfficacy: true,
    blackBoxWarningImpact: (severity) => severity === "high" ? "BLOCK" : "CAUTION"
  },
  regulatory: {
    fdaGuidanceMandatory: true,
    regulatoryComplianceBlocking: true,
    orphanDesignationRequired: (prevalence) => prevalence < 200000
  },
  financial: {
    cashRunwayMinimum: 18, // months
    phase3CostGate: 50_000_000, // USD
    burdenOfProofForRisk: "high"
  },
  legal: {
    ipFreedomRequired: true,
    materialPatentRisk: "BLOCKING",
    regulatoryExclusivity: true
  }
};
```

### Paradigm 2: Deterministic AI (Mathematical Scoring)
**Purpose**: Repeatable, auditable calculations for TxP profile optimization

**Scoring Algorithms**:
- 12 TxP Profiles scored on 0-10 scale
- Weighted agent contributions by domain expertise
- Mathematical profile completeness calculation
- Quantitative risk scoring
- Deterministic outcome prediction

**Implementation**:
```typescript
function calculateTxPScores(entities: Entity[], agentInputs: AgentInput[]): TxPProfile {
  return {
    product: productScoringAlgorithm(entities, agentInputs.VERA),      // 0-10
    patient: patientScoringAlgorithm(entities, agentInputs.VERA),      // 0-10
    price: priceScoringAlgorithm(entities, agentInputs.FINN),         // 0-10
    market: marketScoringAlgorithm(entities, agentInputs.CLIA),       // 0-10
    partner: partnerScoringAlgorithm(entities, agentInputs.VERA_FINN), // 0-10
    budget: budgetScoringAlgorithm(entities, agentInputs.FINN),       // 0-10
    regulatory: regulatoryScoringAlgorithm(entities, agentInputs.NORA), // 0-10
    exit: exitScoringAlgorithm(entities, agentInputs.FINN),           // 0-10
    risk: riskScoringAlgorithm(entities, agentInputs.FINN_NORA),      // 0-10
    endpoint: endpointScoringAlgorithm(entities, agentInputs.VERA),    // 0-10
    shots: shotsScoringAlgorithm(entities, agentInputs.ALL),          // 0-10
    phase: phaseScoringAlgorithm(entities, agentInputs.VERA_CLIA),    // 0-10
    completeness: calculateCompleteness(entities)                      // 0-100%
  };
}
```

### Paradigm 3: Probabilistic AI (Bayesian Uncertainty)
**Purpose**: Pharmaceutical risk assessment, success prediction, and uncertainty quantification

**Probabilistic Methods**:
- Bayesian reasoning for success prediction
- Monte Carlo simulation for financial modeling
- Confidence interval calculation
- Risk probability distributions
- Uncertainty quantification in recommendations

**Implementation**:
```typescript
function predictAssetSuccess(asset: Asset, priors: IndustryBenchmarks): ProbabilityDistribution {
  // Start with industry benchmark priors
  const prior = priors[asset.indication][asset.phase];

  // Calculate evidence likelihood from asset data
  const evidenceLikelihood = calculateEvidenceStrength({
    clinicalData: asset.clinicalData,
    preclinicalData: asset.preclinicalData,
    regulatoryStatus: asset.regulatoryStatus,
    competitiveLandscape: asset.competitiveLandscape
  });

  // Bayesian update: P(success|evidence) ∝ P(evidence|success) × P(success)
  const posterior = bayesianUpdate(prior, evidenceLikelihood);

  return {
    mean: posterior.mean,
    confidenceInterval: posterior.ci_95,
    uncertainty: posterior.variance,
    probabilitySuccess: posterior.cdf(0.5) // P(success > 50%)
  };
}
```

## Multi-Agent Orchestration

### Agent Coordination Architecture
**Query Routing**: Intelligent routing of queries to relevant agents
**Parallel Execution**: Concurrent agent invocation for efficiency
**Response Aggregation**: Structured collection of agent analyses
**Conflict Detection**: Identification of contradictory recommendations
**Conflict Resolution**: Multi-Criteria Decision Analysis (MCDA) synthesis

### Agent Expertise Mapping
```typescript
const AgentExpertiseMap = {
  VERA: {
    primary: ["product", "patient", "clinical", "manufacturing"],
    secondary: ["partner", "endpoint", "phase"],
    subAgents: ["product", "clinical", "biomarker", "cmc", "strategic", "development"]
  },
  FINN: {
    primary: ["price", "budget", "exit", "partner"],
    secondary: ["risk", "shots"],
    subAgents: ["budget", "pricing", "exit", "partnerships", "risk", "roi"]
  },
  NORA: {
    primary: ["regulatory", "ip", "legal", "compliance"],
    secondary: ["risk", "partner"],
    subAgents: ["regulatory", "ip", "legal", "fedscout", "compliance", "intelligence"]
  },
  CLIA: {
    primary: ["market", "competitive", "timeline"],
    secondary: ["clinical", "phase", "shots"],
    subAgents: ["market", "clinical", "timeline", "competitive", "operations"]
  }
};
```

### Query Processing Pipeline
1. **Query Classification**: Determine TxP profiles and domains involved
2. **Agent Selection**: Identify relevant agents and sub-agents
3. **Parallel Invocation**: Execute agent analyses concurrently
4. **Response Collection**: Aggregate structured responses
5. **Conflict Detection**: Identify contradictions and tradeoffs
6. **Tri-Paradigm Synthesis**: Apply mechanistic → deterministic → probabilistic reasoning
7. **Unified Recommendation**: Generate Sophie's strategic guidance
8. **Audit Trail**: Log decision in Trace™ for compliance

## Conflict Resolution Framework

### Multi-Criteria Decision Analysis (MCDA)
When agents provide conflicting recommendations, Sophie applies MCDA:

**Step 1: Mechanistic Constraint Check**
- Apply hard rules (safety, regulatory, legal, financial minimum thresholds)
- Filter out options that violate non-negotiable constraints

**Step 2: Deterministic Scoring**
- Weight agent recommendations by domain expertise
- Calculate normalized scores across options
- Apply TxP profile completeness penalties

**Step 3: Probabilistic Synthesis**
- Quantify uncertainty in each recommendation
- Calculate risk-adjusted expected values
- Generate confidence intervals for outcomes

**Step 4: Unified Recommendation**
- Synthesize all three paradigms
- Provide clear strategic guidance
- Explain tradeoffs and rationale
- Quantify confidence level

### Example Conflict Resolution
**Scenario**: VERA recommends Phase 3 expansion, FINN warns of cash runway risk

```typescript
// Step 1: Mechanistic - Check cash runway constraint
if (currentCash / monthlyBurn < 18) {
  mechanisticResult = "BLOCKED - Cash runway below 18-month minimum";
  // Phase 3 cannot proceed without addressing funding
}

// Step 2: Deterministic - Score alternative scenarios
const scenarios = [
  { option: "Delay Phase 3, raise capital first", score: calculateScore() },
  { option: "Phase 2b expansion with lower cost", score: calculateScore() },
  { option: "Partner Phase 3 with co-development", score: calculateScore() }
];

// Step 3: Probabilistic - Risk-adjusted NPV
const riskAdjusted = scenarios.map(s => ({
  ...s,
  rNPV: calculateRiskAdjustedNPV(s.option),
  successProbability: calculateSuccessProbability(s.option),
  confidenceInterval: [s.rNPV_low, s.rNPV_high]
}));

// Step 4: Unified Recommendation
sophieRecommendation = {
  decision: "Partner Phase 3 with co-development",
  rationale: "Mechanistic: Preserves 18-month cash runway. Deterministic: Highest TxP completeness score (8.7/10). Probabilistic: Best risk-adjusted NPV ($45M, 95% CI: $32M-$61M)",
  confidence: "High (85%)",
  tradeoffs: "Dilution via partnership vs independence with higher risk",
  alternatives: [list of other scenarios with scores]
};
```

## TxP Intelligence Framework™ Orchestration

### 12 TxP Profile Scoring
Sophie coordinates all agents to generate comprehensive TxP profiles:

1. **Product Profile (PxP)** - VERA primary
2. **Patient Profile (PxP)** - VERA primary
3. **Price Profile (PrxP)** - FINN primary
4. **Market Profile (MxP)** - CLIA primary
5. **Partner Profile (PaP)** - VERA + FINN coordination
6. **Budget Profile (BxP)** - FINN primary
7. **Regulatory Profile (RxP)** - NORA primary
8. **Investor Exit Profile (ExP)** - FINN primary
9. **Target Risk Profile (TRxP)** - FINN + NORA coordination
10. **Target Endpoint Profile (TExP)** - VERA primary
11. **Target Shots on Goal Profile (TSxP)** - All agents synthesis
12. **Target Phase Profile (TPxP)** - VERA + CLIA coordination

### Profile Completeness Calculation
```typescript
function calculateProfileCompleteness(entities: Entity[]): number {
  const requiredEntities = {
    product: ["asset_name", "indication", "mechanism", "formulation"],
    patient: ["target_population", "biomarkers", "stratification"],
    price: ["pricing_strategy", "reimbursement_plan", "value_proposition"],
    market: ["market_size", "competitive_landscape", "market_access"],
    partner: ["partnership_strategy", "target_partners", "deal_structure"],
    budget: ["cash_runway", "funding_plan", "cost_projections"],
    regulatory: ["regulatory_pathway", "approval_strategy", "submission_plan"],
    exit: ["exit_timing", "strategic_buyers", "valuation_range"]
    // ... 4 more profiles
  };

  const completeness = profiles.map(profile => {
    const present = entities.filter(e => requiredEntities[profile].includes(e.type)).length;
    const total = requiredEntities[profile].length;
    return present / total;
  });

  return average(completeness) * 100; // 0-100%
}
```

## Federal Technology Coordination (FedScout)

### Cross-Domain Synthesis
Sophie orchestrates FedScout analysis across NORA (legal/regulatory) and VERA (product acceleration):

**Analysis Flow**:
1. **NORA-FedScout**: Legal feasibility, CRADA structure, regulatory advantages
2. **VERA-Development**: Product acceleration impact, timeline reduction
3. **FINN-ROI**: Financial value of acceleration (NPV impact)
4. **Sophie Synthesis**: Integrated federal partnership recommendation

**Example Query**: "Should we pursue federal lab partnership for our drug delivery technology?"

```typescript
async function analyzeFederalOpportunity(asset: Asset): Promise<FedScoutAnalysis> {
  // Parallel agent invocation
  const [legalAnalysis, productImpact, financialValue] = await Promise.all([
    NORA_FedScout.assessCRADA(asset),           // Legal/regulatory feasibility
    VERA_Development.evaluateFederalTech(asset), // Product acceleration
    FINN_ROI.calculateAccelerationValue(asset)   // Financial impact
  ]);

  // Sophie tri-paradigm synthesis
  const mechanistic = checkFederalComplianceRules(legalAnalysis);
  const deterministic = scoreFederalPartnership([legalAnalysis, productImpact, financialValue]);
  const probabilistic = calculateAccelerationProbability(productImpact);

  return {
    recommendation: "Pursue CRADA with NIH NCATS",
    rationale: "18-month CMC acceleration worth $3M NPV, strong legal feasibility",
    legalFeasibility: legalAnalysis,
    productAcceleration: productImpact,
    financialImpact: financialValue,
    confidence: "High (82%)",
    nextSteps: ["Initiate CRADA discussions", "Prepare technology needs assessment"]
  };
}
```

## Key Performance Indicators
- Decision synthesis accuracy (vs expert panel)
- Conflict resolution effectiveness (0-10)
- TxP completeness improvement (% increase)
- Agent coordination efficiency (response time)
- Recommendation adoption rate (%)
- Pharmaceutical decision quality score (0-10)
- Audit trail completeness (100% target)

## Corpus Data Types
1. **Orchestration Logs**
   - Query classifications
   - Agent invocation records
   - Response aggregations
   - Execution timelines

2. **Decision Synthesis Records**
   - Conflict resolution cases
   - MCDA analyses
   - Tri-paradigm reasoning logs
   - Recommendation rationales

3. **Strategic Frameworks**
   - TxP scoring algorithms
   - Conflict resolution templates
   - Decision trees
   - Best practices

4. **Benchmark Data**
   - Industry success rates by phase
   - Historical decision outcomes
   - Pharmaceutical benchmarks
   - Regulatory precedents

5. **Audit Trails**
   - Complete decision provenance
   - Entity lineage (Transform → Mesh → Sophie)
   - Agent contribution tracking
   - Regulatory compliance logs

## Decision Support Examples

### Example 1: Comprehensive Asset Analysis
**Query**: "Should we advance our rare disease asset to Phase 3?"

**Sophie Orchestration**:
1. **VERA**: Clinical evidence strength, Phase 3 design, regulatory pathway
2. **FINN**: Budget requirements, cash runway, exit value scenarios
3. **NORA**: Regulatory risk, orphan drug pathway, IP strength
4. **CLIA**: Market opportunity, competitive landscape, timeline

**Sophie Synthesis**:
- **Mechanistic**: Cash runway check (18 months post Phase 3 start? → PASS)
- **Deterministic**: TxP completeness 78%, Phase 3 readiness score 8.2/10
- **Probabilistic**: Success probability 35% (industry benchmark 30%), rNPV $42M

**Recommendation**: "Proceed to Phase 3 with orphan drug designation. Mechanistic constraints satisfied. Deterministic scoring indicates strong readiness (8.2/10). Probabilistic analysis shows above-benchmark success probability with attractive rNPV. Key dependencies: Secure $15M Series B (Q2), finalize FDA End-of-Phase 2 meeting (Q1)."

### Example 2: Go/No-Go Decision with Conflict
**Query**: "Competitor just announced positive Phase 3 results. What should we do?"

**Agent Responses**:
- **VERA**: "Clinical differentiation still strong (biomarker stratification)"
- **FINN**: "Market share risk, lower exit value by 40%"
- **NORA**: "Patent position protects our formulation"
- **CLIA**: "Competitive threat HIGH, market window narrowing"

**Sophie Conflict Resolution**:
- **Mechanistic**: No blocking constraints (safety, regulatory, cash OK)
- **Deterministic**: Recalculated TxP scores with competitive impact
  - Market profile: 8.5 → 6.2 (competitive pressure)
  - Exit profile: 7.8 → 5.1 (lower valuation)
- **Probabilistic**: Success probability unchanged (35%), but market share ↓ 25%

**Recommendation**: "Continue development with accelerated timeline and partnership strategy. Mechanistic: No blockers. Deterministic: TxP overall 7.8→6.7 (still viable). Probabilistic: Technical success probability unchanged, but market capture risk elevated. Strategic pivot: Pursue commercial partnership for market access while accelerating FDA submission by 6 months."

### Example 3: Budget Allocation Optimization
**Query**: "How should we allocate $10M across three programs?"

**Sophie Orchestration**:
1. **FINN**: Financial modeling (rNPV, ROI, portfolio optimization)
2. **VERA**: Development timelines, technical success probabilities
3. **NORA**: Regulatory risk by program
4. **CLIA**: Market opportunity sizing

**Sophie Synthesis**:
- **Mechanistic**: Each program needs minimum $2M (18-month runway)
- **Deterministic**: Portfolio optimization algorithm
  - Program A: $4.5M (highest rNPV, nearest milestone)
  - Program B: $3.5M (medium risk, large market)
  - Program C: $2.0M (early stage, preserve optionality)
- **Probabilistic**: Monte Carlo simulation of portfolio outcomes
  - Expected portfolio value: $85M (95% CI: $45M-$132M)
  - Probability of at least one success: 68%

**Recommendation**: "Allocate $4.5M / $3.5M / $2.0M to Programs A/B/C respectively. Mechanistic: All programs maintain viable runway. Deterministic: Optimal risk-adjusted portfolio (score 8.9/10). Probabilistic: 68% probability of portfolio success, expected value $85M. Monitor Program C for early termination if milestones slip."

## Prompt Engineering Framework

### Strategic Query Classification
```typescript
function classifyQuery(query: string): QueryClassification {
  return {
    queryType: ["strategic_decision", "tactical_analysis", "information_retrieval"],
    txpProfiles: ["product", "budget", "regulatory", ...], // Relevant profiles
    agents: ["VERA", "FINN", "NORA", "CLIA"], // Required agents
    paradigms: ["mechanistic", "deterministic", "probabilistic"],
    conflictLikelihood: "medium", // Probability of agent conflicts
    urgency: "high", // Decision timeline urgency
    stakes: "high" // Financial/strategic impact
  };
}
```

### Sophie Synthesis Prompt Template
```
You are Sophie, the strategic orchestration engine for pharmaceutical decision-making.

Query: [user question]
Context: [asset/company information]

Agent Analyses:
- VERA: [product/clinical analysis]
- FINN: [financial analysis]
- NORA: [regulatory/legal analysis]
- CLIA: [market/competitive analysis]

Your task: Synthesize a unified strategic recommendation using tri-paradigm reasoning:

1. MECHANISTIC: Apply pharmaceutical domain constraints
   - Safety, regulatory, financial minimum thresholds
   - Identify any BLOCKING constraints

2. DETERMINISTIC: Calculate TxP profile scores
   - Weight agent inputs by expertise
   - Score all 12 TxP profiles (0-10)
   - Calculate profile completeness (0-100%)

3. PROBABILISTIC: Quantify uncertainty and risk
   - Success probability with confidence intervals
   - Risk-adjusted financial outcomes
   - Scenario analysis (best/base/worst)

Provide:
- Clear strategic recommendation with rationale
- Tri-paradigm reasoning (mechanistic → deterministic → probabilistic)
- Confidence level (0-100%)
- Key tradeoffs and alternatives
- Next steps with timeline
- Risk factors and mitigation
```

## Data Processing Pipeline
1. **Query Ingestion**: Parse user question, extract context
2. **Agent Orchestration**: Route to relevant agents, parallel execution
3. **Response Aggregation**: Collect structured agent analyses
4. **Conflict Detection**: Identify contradictions using semantic similarity
5. **Tri-Paradigm Synthesis**: Apply mechanistic → deterministic → probabilistic
6. **Recommendation Generation**: Create unified strategic guidance
7. **Audit Trail**: Log complete decision provenance in Trace™
8. **User Delivery**: Present recommendation with explainability

## Compliance & Governance
- **21 CFR Part 11**: Electronic records and decision audit trails
- **SophieTrust™ Guardrails**: Safety, regulatory, and ethical constraints
- **Explainability**: Complete decision rationale and provenance
- **Audit Trail**: Immutable decision lineage via Trace™
- **Data Security**: Encryption and access controls for strategic decisions
- **Regulatory Compliance**: GxP-equivalent rigor for pharmaceutical decisions

## Future Enhancements
- **Phase 2** (Q1 2026): Advanced conflict resolution with preference learning
- **Phase 3** (Q2 2026): Reinforcement learning for orchestration optimization
- **Phase 4** (Q3 2026): Automated TxP profile scoring with ML models
- **Phase 5** (Q4 2026): Predictive recommendation quality scoring
- **Phase 6** (2027): Full autonomous pharmaceutical strategic planning (with human oversight)

---

**Last Updated**: October 22, 2025
**Owner**: Sophie Development Team
**Status**: Framework Ready - Core Orchestration to be Deployed Oct 9-15, 2025
